European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Fibrinolysis in ovarian cancer
Coagulation disorders, including thromboembolic phenomena and disseminated intravascular coagulation are recognised as a complication of neoplastic disease. In the present study the Fibrinogen Degradation Products (F.D.P.) were determined in 26 patients with Advanced Ovarian Cancer (stage III and IV FIGO)（x＝ 38.1; S.D. = 37.6) and in ten healthy patients considered as controls（x＝ 2.7; S.D. = 1.3). The significative difference (p < 0.05) between the two groups points in evidence an increasing activation of fibrynolitic processes. The F.D.P. determination has revealed a good correlation (p < 0.001) with the tumor extension as showed by the difference between third stage with large tumor masses (late)（x＝ 44.5; S.D. = 24.5) and third stage with minimal residual disease after reductive surgery (early)（x＝ 6.7; S.D. = 5.7).